Drug
M7824
M7824: highest development phase Phase 1, developed by Merck KGaA. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| M7824 NCT04551950 | Phase 1 | Cervical Cancer |
Latest
No recent events.
Follow M7824 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.